Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Murcko

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Frontiers in Molecular Biosciences|December 9, 2022
Principles and functions of condensate modifying drugsAvinash Patel, Diana Mitrea, Vigneshwaran Namasivayam, et al.
Nature Reviews. Drug Discovery|August 16, 2022
Modulating biomolecular condensates: a novel approach to drug discoveryDiana M Mitrea, Matthäus Mittasch, Beatriz Ferreira Gomes, et al.
Bioorganic & Medicinal Chemistry Letters|May 8, 2007
Inhibitors of hepatitis C virus NS3.4A protease. Effect of P4 capping groups on inhibitory potency and pharmacokineticsRobert B Perni, Gurudatt Chandorkar, Kevin M Cottrell, et al.
Antimicrobial Agents and Chemotherapy|December 31, 2014
Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunitRandal A Byrn, Steven M Jones, Hamilton B Bennett, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
The Discovery of VX-745: A Novel and Selective p38α Kinase InhibitorJohn P Duffy, Edmund M Harrington, Francesco G Salituro, et al.
Bioorganic & Medicinal Chemistry Letters|March 31, 2004
Inhibitors of hepatitis C virus NS3.4A protease. Part 3: P2 proline variantsRobert B Perni, Luc J Farmer, Kevin M Cottrell, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Frontiers in Molecular Biosciences|December 9, 2022
Principles and functions of condensate modifying drugsAvinash Patel, Diana Mitrea, Vigneshwaran Namasivayam, et al.
Nature Reviews. Drug Discovery|August 16, 2022
Modulating biomolecular condensates: a novel approach to drug discoveryDiana M Mitrea, Matthäus Mittasch, Beatriz Ferreira Gomes, et al.
Bioorganic & Medicinal Chemistry Letters|May 8, 2007
Inhibitors of hepatitis C virus NS3.4A protease. Effect of P4 capping groups on inhibitory potency and pharmacokineticsRobert B Perni, Gurudatt Chandorkar, Kevin M Cottrell, et al.
Antimicrobial Agents and Chemotherapy|December 31, 2014
Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunitRandal A Byrn, Steven M Jones, Hamilton B Bennett, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
The Discovery of VX-745: A Novel and Selective p38α Kinase InhibitorJohn P Duffy, Edmund M Harrington, Francesco G Salituro, et al.
Bioorganic & Medicinal Chemistry Letters|March 31, 2004
Inhibitors of hepatitis C virus NS3.4A protease. Part 3: P2 proline variantsRobert B Perni, Luc J Farmer, Kevin M Cottrell, et al.
Pageof 2